KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Short term Debt (2016 - 2025)

Astrazeneca (AZN) has 3 years of Short term Debt data on record, last reported at $3.1 billion in Q4 2025.

  • For Q4 2025, Short term Debt rose 32.82% year-over-year to $3.1 billion; the TTM value through Dec 2025 reached $3.1 billion, up 32.82%, while the annual FY2025 figure was $3.1 billion, 32.82% up from the prior year.
  • Short term Debt reached $3.1 billion in Q4 2025 per AZN's latest filing, up from $2.3 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $5.1 billion in Q4 2023 and bottomed at $2.3 billion in Q4 2024.
  • Average Short term Debt over 3 years is $3.5 billion, with a median of $3.1 billion recorded in 2025.
  • Peak YoY movement for Short term Debt: tumbled 54.44% in 2024, then skyrocketed 32.82% in 2025.
  • A 3-year view of Short term Debt shows it stood at $5.1 billion in 2023, then crashed by 54.44% to $2.3 billion in 2024, then skyrocketed by 32.82% to $3.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $3.1 billion in Q4 2025, $2.3 billion in Q4 2024, and $5.1 billion in Q4 2023.